Who we are…

Genesis Health System Office of Research and Grants Administration is here to help you. If you need assistance please contact us.

Sarah Castro Research Support Liaison (563) 421-7957 castros@genesishealth.com

Joy Lemmon Research Program Coordinator (563) 421-7956 lemmonjoy@genesishealth.com

Genesis Health System Research Promotion Fund To make a request to use the monies in the Research Promotion Fund, go to www.genesishealth.com/research and fill out the online application. You can also contact the Office of Research and Grants Administration for a copy of the application.

Once the Research Promotion Fund Committee receives a completed form, the committee does it's best to respond to applications within two weeks.

If you have questions about the Genesis Health System Research Promotion Fund, please direct them to Sarah Castro at CastroS@genesishealth.com.

Tools for Researchers

The Genesis Research Department has created a number of IRB approved tools and templates to assist researchers in developing new studies. These tools can be found on the Genesis Research website at — www.genesishealth.com/research.

Research Checklist — Outlines the documents to prepare and activities to complete for a research study. It also provides a description of each document and instructions for where to find helpful resources. Protocol Template — Outlines the sections and information that should be included in a research protocol. A protocol outlines how a research study will be conducted. Informed Consent — Outlines the sections and information that should be included Template in an informed consent. It also provides suggested language and general instructions regarding the informed consent process. Research Trainings – Provides instructions on the required research trainings and where to access them.

http://www.genesishealth.com/research

Genesis Research Inquirer September/October 2017

Congratulations — Proposal Accepted!

Congratulations to the Dynavision research team for being accepted for presentation at the 2018 American Occupational Therapy Association (AOTA) Annual Conference & Expo! The researchers have been working on a study for over 3 years to collect normative data for visual reaction speed, physical response speed and motor response time for the Dynavision D2 Visuomotor Training System. The research team includes the following individuals: Cherie Blackwell, Kristen Mandle, Kami Holst, Kathy Cary, Sue Clemens, Lori Dryg, Jon Lemke, Ryan Kelly and Emma Hendricks. They will be presenting a poster at the AOTA conference which is

being held on April 19-22, 2018 in Salt Lake City, UT. The research team is currently preparing a manuscript to be submitted for publication.

Attention All Therapists, We Need Your Feedback

Continuing to strive towards excellence in quality rehabilitation services is essential as demands for outcome measures and use of evidence-based practice are becoming requirements to support therapy treatment sessions. Moving toward these objectives to utilize research within the rehabilitation services at Genesis, a research subcommittee has been formed. This committee would like to understand the needs of all inpatient/outpatient Genesis therapists. A brief survey has been created to assess how the research subcommittee can best serve Genesis therapists’ research needs. If you are a Genesis inpatient or outpatient therapist, please consider helping this subcommittee by completing the survey linked below. It should take you about 5-10 minutes to complete. The survey will close on November 17, 2017. https://www.surveymonkey.com/r/3KVQR9H

REMINDER — Trainings Scheduled for New Research Policy Changes

On January 19, 2018, revisions to the Federal Policy for the Protection of Human Subjects (the Common Rule) will go into effect. In order to ensure all researchers at Genesis are fully informed about the Common Rule changes and how that will affect processes at Genesis, the Research Department will be holding two trainings in November.

TRAINING SCHEDULE

If you have any questions about these trainings or the upcoming changes to the research policies, please contact Sarah Castro at castros@genesishealth.com or 563-421-7957.

Date Time Location

Wednesday, November 8 12:00—1:30 pm Adler 1 Genesis East Campus

Thursday, November 9 5:00—6:30 pm Interconnect Lounge Medical Office Building 1

Genesis East Campus

Ask the Librarian/Literature Request Form Now on GENnet When you have a question for the medical librarian or you would like her to do a literature search, go to the Clinical Library page in GENnet. On the right side of the page, at the top, you will find a link to the form. Fill it out, submit it, and it will go directly to the medical librarian. You may still e-mail the librarian directly, if you wish. This form will be a way to better serve the needs of Genesis colleagues. If you have any questions, please contact Karlene Campbell, Medical Librarian, by phone at (563) 421-2287; (309) 281-5110; or email campbellka@genesishealth.com.

2018 Genesis IRB Schedule The 2018 Genesis Institutional Review Board meeting schedule is now available on the Research website at http://www.genesishealth.com/about/research_grants/genesis-institutional-review-board/

Genesis Research Inquirer September/October 2017

Nursing Evidence-Based Practice (EBP) Internship Genesis will again be offering its Nursing Evidence-Based Practice Internship in 2018! The Internship is designed to assist staff nurse, nurse manager (NM), and Nursing Research and EBP committee member teams in developing a clinically relevant EBP project for their clinical area. Each staff nurse intern will work with peers to implement a practice change in their clinical area. The Internship program includes coursework, team meetings, and project work time. Benefits For Staff

Opportunity to improve patient care Recognition for impact on patient care Support to facilitate the staff nurse’s project Free CEU’s 12-days of paid non-patient care time within a negotiated work schedule

Applications are available from GENnet (GENnet > Nursing > Nursing Research and EBP Committee). The application deadline is December 31, 2017. Contact Amanda Wesson for more information at 421-7667.

Approved New Projects: Two Studies in Sep - Oct, 2017 Psychological Changes in Cancer Patients Receiving a Biobehavioral Intervention (BBI)(From Cancer to HealthTM): A Program Evaluation Principal Investigator: Melissa Wright, LMSW, OSW-C Rationale and Purpose: The purpose of this study is to assess the effectiveness of a biobehavioral intervention called From Cancer to HealthTM with cancer patients by measuring patient self reported distress pre and post treatment. Factors Affecting Satisfaction with Childbirth at a Community Hospital Principal Investigator: Lisa Andresen RN, MSN and Kim Nimrick, MSN, RNC-OB Rationale and Purpose: The purpose of this study is to examine the factors associated with childbirth satisfaction among mothers at Genesis Medical Center, Davenport. The study is specifically interested in the role of pain relief methods on satisfaction.

http://www.genesishealth.com/about/research_grants/genesis-institutional-review-board/

Completed Studies —Seven Studies in Sep - Oct, 2017 CALGB 49906: A Phase III Study of Doxorubicin/Cyclophosphamide Therapy Followed By Paclitaxel or Docetaxel Given Weekly or Every 3 Weeks with Axillary Node- Positive or High Risk Node Negative Breast Cancer Principal Investigator: Dr. Shobha Chitneni Rationale and Purpose: To determine whether docetaxel improves disease-free survival and overall survival when compared to paclitaxel following 4 cycles of doxorubicin-cyclophosphamide therapy. Results: Results pending ALLIANCE A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST) Principal Investigator: Dr. Shoba Chitneni Rationale and Purpose: To examine lung cancer patients’ tumors that were removed by surgery for certain genetic changes, and to possibly offer these patients a treatment study with drugs that may specifically target tumors that have these genetic changes. Results: Study is being transferred to the University of Iowa IRB ECOG-ACRIN EA5142: Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers Principal Investigator: Dr. Shobha Chitneni Rationale and Purpose: To evaluate whether adjuvant therapy with nivolumab will result in improved overall survival (OS) and/or disease-free survival (DFS) over standard observation in patients with Stage IB≥4cm, II and IIIA, NSCLC following surgical resection and standard adjuvant therapy. Results: Study is being transferred to the University of Iowa IRB COCOA: Collaborative Care of Older Adults with Back Pain: Clinical Trial Principal Investigator: Dr. Andrew Andresen Rationale and Purpose: To develop, refine, and test an integrative model for patient-centered collaborative care between medical doctors or doctors of osteopathy (MDs/DOs) and doctors of chiropractic (DCs) in an older adult population with back pain. Results: Results pending The Prevalence and Cost of Unindicated Pre-Operative Diagnostic Testing for Elective Shoulder, Knee and Hip Surgeries Principal Investigator: Matthew Arnold, PharmD Rationale and Purpose: To identify the number of pre-operative tests conducted for elective shoulder, knee and hip surgeries at Genesis Medical Center, Davenport that did not follow the American College of Cardiology/American Heart Association guidelines, between January 2014 and June 2014. Results: A total of 1,814 pre-operative tests were ordered on the 301 patients. Of these tests, only 172 (9.5%) were indicated while the remaining 1,642 (90.5%) were unindicated. We used the 2014 Medicare charge to cost ratio to determine the actual cost of unindicated pre-operative testing, yielding a cost per 1,000 patients of $251,355 (95% CI $227,613- $277,613). NRG-BR003: Testing the addition of carboplatin to usual chemotherapy in high risk triple-negative breast cancer Principal Investigator: Dr. Shobha Chitneni Rationale and Purpose: To determine whether the addition of carboplatin to an adjuvant chemotherapy regimen of doxorubicin/cyclophosphamide followed by paclitzxel will improve the invasive disease-free survival compared to doxorubicin/cyclophosphamide followed by paclitzxel when administered to patients with operable node-positive or high-risk node-negative triple-negative breast cancer. Results: Study is being transferred to the University of Iowa IRB S1207 Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer Principal Investigator: Dr. Shobha Chitneni Rationale and Purpose: To compare whether the addition of one year of everolimus (10 mg daily) to standard adjuvant endocrine therapy improves invasive disease-free survival (IDFS) in patients with high-risk, hormone-receptor (HR) positive and HER2-negative breast cancer. Results: Study is being transferred to the University of Iowa IRB

Genesis Research Inquirer September/October 2017